Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 93

1.

A Phase II Clinical Trial of TRC105 (Anti-Endoglin Antibody) in Adults With Advanced/Metastatic Urothelial Carcinoma.

Apolo AB, Karzai FH, Trepel JB, Alarcon S, Lee S, Lee MJ, Tomita Y, Cao L, Yu Y, Merino MJ, Madan RA, Parnes HL, Steinberg SM, Rodriguez BW, Seon BK, Gulley JL, Arlen PM, Dawson NA, Figg WD, Dahut WL.

Clin Genitourin Cancer. 2017 Feb;15(1):77-85. doi: 10.1016/j.clgc.2016.05.010. Epub 2016 May 27.

PMID:
27328856
2.

An open-label phase Ib dose-escalation study of TRC105 (anti-endoglin antibody) with bevacizumab in patients with advanced cancer.

Gordon MS, Robert F, Matei D, Mendelson DS, Goldman JW, Chiorean EG, Strother RM, Seon BK, Figg WD, Peer CJ, Alvarez D, Adams BJ, Theuer CP, Rosen LS.

Clin Cancer Res. 2014 Dec 1;20(23):5918-26. doi: 10.1158/1078-0432.CCR-14-1143. Epub 2014 Sep 26.

3.

Facilitation of endoglin-targeting cancer therapy by development/utilization of a novel genetically engineered mouse model expressing humanized endoglin (CD105).

Toi H, Tsujie M, Haruta Y, Fujita K, Duzen J, Seon BK.

Int J Cancer. 2015 Jan 15;136(2):452-61. doi: 10.1002/ijc.28994. Epub 2014 Jun 13.

4.

A phase I first-in-human study of TRC105 (Anti-Endoglin Antibody) in patients with advanced cancer.

Rosen LS, Hurwitz HI, Wong MK, Goldman J, Mendelson DS, Figg WD, Spencer S, Adams BJ, Alvarez D, Seon BK, Theuer CP, Leigh BR, Gordon MS.

Clin Cancer Res. 2012 Sep 1;18(17):4820-9. doi: 10.1158/1078-0432.CCR-12-0098. Epub 2012 Jul 5.

5.

Endoglin-targeted cancer therapy.

Seon BK, Haba A, Matsuno F, Takahashi N, Tsujie M, She X, Harada N, Uneda S, Tsujie T, Toi H, Tsai H, Haruta Y.

Curr Drug Deliv. 2011 Jan;8(1):135-43. Review.

6.

Receptor-targeted anticancer therapy.

Seon BK, Haruta Y, Matsuno F, Haba A, Takahashi N, She X, Harada N, Uneda S, Tsujie M, Tsujie T, Toi H, Tsai H.

Immunol Res. 2010 Mar;46(1-3):189-91. doi: 10.1007/s12026-009-8131-8. Review. No abstract available.

7.

Anti-endoglin monoclonal antibodies are effective for suppressing metastasis and the primary tumors by targeting tumor vasculature.

Uneda S, Toi H, Tsujie T, Tsujie M, Harada N, Tsai H, Seon BK.

Int J Cancer. 2009 Sep 15;125(6):1446-53. doi: 10.1002/ijc.24482.

8.

Anti-tumor activity of an anti-endoglin monoclonal antibody is enhanced in immunocompetent mice.

Tsujie M, Tsujie T, Toi H, Uneda S, Shiozaki K, Tsai H, Seon BK.

Int J Cancer. 2008 May 15;122(10):2266-73. doi: 10.1002/ijc.23314.

10.

Antiangiogenic chimeric anti-endoglin (CD105) antibody: pharmacokinetics and immunogenicity in nonhuman primates and effects of doxorubicin.

Shiozaki K, Harada N, Greco WR, Haba A, Uneda S, Tsai H, Seon BK.

Cancer Immunol Immunother. 2006 Feb;55(2):140-50. Epub 2005 Apr 23.

PMID:
15856228
11.
12.

Both high intratumoral microvessel density determined using CD105 antibody and elevated plasma levels of CD105 in colorectal cancer patients correlate with poor prognosis.

Li C, Gardy R, Seon BK, Duff SE, Abdalla S, Renehan A, O'Dwyer ST, Haboubi N, Kumar S.

Br J Cancer. 2003 May 6;88(9):1424-31.

13.

Expression of endoglin (CD105) in tumor blood vessels.

Seon BK.

Int J Cancer. 2002 May 10;99(2):310-1; author reply 312. No abstract available.

14.

Angiogenesis and metastasis marker of human tumors.

Seon BK, Takahashi N, Haba A, Matsuno F, Haruta Y, She XW, Harada N, Tsai H.

Rinsho Byori. 2001 Oct;49(10):1005-13.

PMID:
11769465
16.

Association of serum endoglin with metastasis in patients with colorectal, breast, and other solid tumors, and suppressive effect of chemotherapy on the serum endoglin.

Takahashi N, Kawanishi-Tabata R, Haba A, Tabata M, Haruta Y, Tsai H, Seon BK.

Clin Cancer Res. 2001 Mar;7(3):524-32.

17.

Differential behavior of VEGF receptor expression and response to TNP-470 in two immortalized human endothelial cell lines.

Seki M, Toi M, Kobayashi K, Shitara K, Umezawa K, Seon BK, Kan M, Rhim JS.

Int J Oncol. 2000 Sep;17(3):525-33.

PMID:
10938394
18.
19.
20.

Cross-linking of antigen receptor via Ig-beta (B29, CD79b) can induce both positive and negative signals in CD40-activated human B cells.

Van Kooten C, Galibert L, Seon BK, Garrone P, Liu YJ, Banchereau J.

Clin Exp Immunol. 1997 Dec;110(3):509-15.

21.

Improvement of the chronic lymphocytic leukemia scoring system with the monoclonal antibody SN8 (CD79b).

Moreau EJ, Matutes E, A'Hern RP, Morilla AM, Morilla RM, Owusu-Ankomah KA, Seon BK, Catovsky D.

Am J Clin Pathol. 1997 Oct;108(4):378-82.

PMID:
9322589
22.
24.

Expression of the immunoglobulin-associated protein B29 in B cell disorders with the monoclonal antibody SN8 (CD79b).

Zomas AP, Matutes E, Morilla R, Owusu-Ankomah K, Seon BK, Catovsky D.

Leukemia. 1996 Dec;10(12):1966-70.

PMID:
8946938
25.

Differential expression of B29 (CD79b) and mb-1 (CD79a) proteins in acute lymphoblastic leukaemia.

Astsaturov IA, Matutes E, Morilla R, Seon BK, Mason DY, Farahat N, Catovsky D.

Leukemia. 1996 May;10(5):769-73.

PMID:
8656670
26.

Similarity of TALLA-1, a T-cell acute lymphoblastic leukemia antigen, to GP37.

Seon BK.

Int J Cancer. 1995 Nov 3;63(3):474. No abstract available.

PMID:
7591251
27.

Immune responses in patients with T-cell lymphoma treated with an anti-idiotype antibody mimicking a highly restricted T-cell antigen.

Foon KA, Oseroff AR, Vaickus L, Greenberg SJ, Russell D, Bernstein Z, Pincus S, Köhler H, Seon BK, Tahaoglu E, et al.

Clin Cancer Res. 1995 Nov;1(11):1285-94.

29.

Isolation and chemical characterization of the human B29 and mb-1 proteins of the B cell antigen receptor complex.

Vasile S, Coligan JE, Yoshida M, Seon BK.

Mol Immunol. 1994 Apr;31(6):419-27.

PMID:
7514267
35.
36.

In vitro and in vivo cytotoxic activity of anti-human leukemia monoclonal antibodies SN5c and SN6 daunorubicin conjugates.

Biddle WC, Haruta Y, Seon BK, Henderson ES, Sarcione EJ.

Leuk Res. 1989;13(8):699-707.

PMID:
2529399
38.

Idiotype vaccines against human T cell leukemia. II. Generation and characterization of a monoclonal idiotype cascade (Ab1, Ab2, and Ab3).

Bhattacharya-Chatterjee M, Chatterjee SK, Vasile S, Seon BK, Kohler H.

J Immunol. 1988 Aug 15;141(4):1398-403.

PMID:
2899603
39.
40.
41.
42.

Unique epitopes of common acute lymphoblastic leukemia antigen detected by new monoclonal antibodies.

Matsuzaki H, Haruta Y, Fukukawa T, Barcos MP, Seon BK.

Cancer Res. 1987 Apr 15;47(8):2160-6.

43.

Follicular mantle zone cell subpopulations detected by monoclonal antibody SN3.

Barcos M, Pollard C, Fukukawa T, Seon BK.

Hematol Oncol. 1986 Oct-Dec;4(4):251-9.

PMID:
3493967
44.

New monoclonal antibodies SN3, SN3a, and SN3b directed to sialic acid of glycoprotein on human non-T leukemia cells.

Fukukawa T, Matsuzaki H, Haruta Y, Hara H, Seon BK.

Exp Hematol. 1986 Oct;14(9):850-5.

PMID:
3489635
45.
46.

Human T-cell leukemia-associated cell surface glycoprotein GP37: studies with three monoclonal antibodies and a rabbit antiserum.

Seon BK, Fukukawa T, Jackson AL, Chervinsky D, Tebbi CK, Freeman AI, Matsuzaki H.

Mol Immunol. 1986 Jun;23(6):569-80.

PMID:
3489164
47.

Simple solid-phase radioimmunoassay for human leukemia-associated cell membrane antigens.

Matsuzaki H, Fukukawa T, Seon BK.

J Immunol Methods. 1985 Jul 16;81(1):55-63.

PMID:
2991385
49.

Monoclonal antibody SN2 defining a human T cell leukemia-associated cell surface glycoprotein.

Seon BK, Negoro S, Barcos MP, Tebbi CK, Chervinsky D, Fukukawa T.

J Immunol. 1984 Apr;132(4):2089-95.

PMID:
6607954

Supplemental Content

Support Center